## **CLAIM LISTING**

Please find below a complete listing of presently pending claims with status identifiers. This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1-19. Cancelled.
- 20. (Currently Amended) [[A]] <u>An implantable</u> fixed tissue comprising cross-linked elastin, wherein the elastin <u>of the implantable fixed tissue</u> is cross-linked with a phenolic tannin cross-linking agent, the implantable fixed tissue including a residue of the phenolic tannin cross-linking agent.
- 21. (Currently Amended) The fixed tissue of claim [[21]] <u>20</u>, further comprising cross-linked collagen, wherein the collagen is cross-linked with a glutaraldehyde cross-linking agent.
- 22. (Currently Amended) The fixed tissue of claim [[21]] <u>20</u>, wherein the <u>implantable fixed</u> tissue exhibits at least about 60% less calcification over time as compared to <u>a similar a second implantable fixed</u> tissue <u>of the same tissue type</u> fixed with only a glutaraldehyde fixative.
- 23. (Currently Amended) The fixed tissue of claim 20, wherein the <u>implantable</u> fixed tissue comprises at least about 10% elastin by weight.
- 24. (Original) The fixed tissue of claim 20, wherein the phenolic tannin cross-linking agent is tannic acid.
- 25. (Currently Amended) The fixed tissue of claim 20, wherein the <u>implantable</u> fixed tissue has a temperature of thermal denaturation greater than about 70°C.
- 26. (Currently Amended) The fixed tissue of claim 20, wherein the <u>implantable</u> fixed tissue has a temperature of thermal denaturation greater than about 80°C.
- 27. (Currently Amended) The fixed tissue of claim 20, wherein the <u>implantable</u> fixed tissue exhibits less than about 20% degradation following exposure to <u>an</u> elastase <u>enzyme</u> for a period of about 48 hours.
- 28. (Original) The fixed tissue of claim 20, wherein the tissue is selected from the group consisting of bovine and porcine tissue.

- 29. (Original) The fixed tissue of claim 20, wherein the tissue is selected from the group consisting of pericardium, aortic wall, heart valve, and vena cava tissue.
  - 30. (Withdrawn-Currently Amended) A bioprosthesis comprising:

[[a]] <u>an implantable</u> fixed tissue comprising elastin, <u>wherein said elastin is</u> cross-linked with a <u>tannic acid phenolic tannin</u> cross-linking agent, <u>the implantable fixed</u> <u>tissue comprising the residue of the phenolic tannin cross-linking agent</u>; and

a support material attached to the implantable fixed tissue.

- 31. (Withdrawn-Currently Amended) The bioprosthesis of claim 30, in which the <u>implantable fixed</u> tissue has an elastin content of greater than about 10% by weight of the tissue.
- 32. (Withdrawn-Currently Amended) The bioprosthesis of claim 30, in which the <u>implantable fixed</u> tissue further comprises collagen, <u>wherein said collagen is</u> cross-linked with a glutaraldehyde cross-linking agent.
- 33. (Withdrawn-Currently Amended) The bioprosthesis of claim 30, wherein the implantable fixed tissue is an anisotropic tissue.
- 34. (Withdrawn) The bioprosthesis of claim 33, wherein the anisotropic tissue exhibits greater stiffness in a first direction and greater elasticity in a second direction.
- 35. (Withdrawn) The bioprosthesis of claim 30, wherein the tissue is selected from the group consisting of pericardium, aortic wall, heart valve and vena cava tissue.
- 36. (Withdrawn) The bioprosthesis of claim 30, wherein the tissue is porcine vena cava tissue.
- 37. (Withdrawn) The bioprosthesis of claim 30, wherein the support material comprises a stent.
- 38. (Withdrawn) The bioprosthesis of claim 30, wherein the support material comprises a suture ring.
- 39. (Withdrawn) The bioprosthesis of claim 30, wherein the bioprosthesis is a bioprosthetic heart valve.
- 40. (Withdrawn) The bioprosthesis of claim 30, wherein the bioprosthesis exhibits at least about 60% less calcification over time as compared to a similar second

Appl. No. 10/722,142
Response Dated June 30, 2006
Reply to Office Action of April 6, 2006

bioprosthesis <u>comprising a fixed tissue of the same tissue type</u> in which the <u>fixed</u> tissue <u>of the second bioprosthesis</u> is fixed with only glutaraldehyde.

41-46. Cancelled.

47. (New) The bioprosthesis of claim 30, wherein the phenolic tannin cross-linking agent is tannic acid.